DE102017012109A1 - Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis - Google Patents

Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis Download PDF

Info

Publication number
DE102017012109A1
DE102017012109A1 DE102017012109.5A DE102017012109A DE102017012109A1 DE 102017012109 A1 DE102017012109 A1 DE 102017012109A1 DE 102017012109 A DE102017012109 A DE 102017012109A DE 102017012109 A1 DE102017012109 A1 DE 102017012109A1
Authority
DE
Germany
Prior art keywords
lactis
lactis strain
strain
lac4
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102017012109.5A
Other languages
German (de)
English (en)
Inventor
Caspar Hürlimann
Martina Behrens
Mandy Gebauer
Karin Breunig
Sven-Erik Behrens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verovaccines De GmbH
Original Assignee
Martin Luther Univ Halle Wittenberg
Martin Luther Universitaet Halle Wittenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin Luther Univ Halle Wittenberg, Martin Luther Universitaet Halle Wittenberg filed Critical Martin Luther Univ Halle Wittenberg
Priority to DE102017012109.5A priority Critical patent/DE102017012109A1/de
Priority to HRP20241297TT priority patent/HRP20241297T1/hr
Priority to EP18857443.8A priority patent/EP3732293B1/de
Priority to CA3086598A priority patent/CA3086598A1/en
Priority to EA202091435A priority patent/EA202091435A1/ru
Priority to MX2020006846A priority patent/MX2020006846A/es
Priority to DK18857443.8T priority patent/DK3732293T3/da
Priority to JP2020555291A priority patent/JP7782951B2/ja
Priority to KR1020207021778A priority patent/KR102704217B1/ko
Priority to HUE18857443A priority patent/HUE068358T2/hu
Priority to US16/958,170 priority patent/US11905517B2/en
Priority to ES18857443T priority patent/ES2990197T3/es
Priority to PCT/DE2018/000379 priority patent/WO2019129321A2/de
Priority to DE112018006647.9T priority patent/DE112018006647A5/de
Priority to PL18857443.8T priority patent/PL3732293T3/pl
Priority to PT188574438T priority patent/PT3732293T/pt
Priority to CN201880083894.1A priority patent/CN111801422B/zh
Priority to BR112020013245-4A priority patent/BR112020013245A2/pt
Publication of DE102017012109A1 publication Critical patent/DE102017012109A1/de
Priority to ZA2020/03553A priority patent/ZA202003553B/en
Priority to JP2023132434A priority patent/JP2023166412A/ja
Priority to US18/481,345 priority patent/US12473562B2/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
DE102017012109.5A 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis Ceased DE102017012109A1 (de)

Priority Applications (21)

Application Number Priority Date Filing Date Title
DE102017012109.5A DE102017012109A1 (de) 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
PCT/DE2018/000379 WO2019129321A2 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis
ES18857443T ES2990197T3 (es) 2017-12-27 2018-12-19 Sistema de hospedador/vector optimizado para la generación de vacunas de subunidades mono- y multivalentes protectoras a base de la levadura Kluyveromyces lactis
CA3086598A CA3086598A1 (en) 2017-12-27 2018-12-19 Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast kluyveromyces lactis
EA202091435A EA202091435A1 (ru) 2017-12-27 2018-12-19 Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis
MX2020006846A MX2020006846A (es) 2017-12-27 2018-12-19 Sistema de hospedero/vector optimizado para la produccion de vacunas subunitarias monovalentes y multivalentes protectoras con base en la levadura de kluyveromyces lactis.
DK18857443.8T DK3732293T3 (da) 2017-12-27 2018-12-19 Optimeret vært/vektor-system til fremstilling af beskyttende mono- og multivalente subunit-vacciner baseret på gæren kluyveromyces lactis
JP2020555291A JP7782951B2 (ja) 2017-12-27 2018-12-19 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム
KR1020207021778A KR102704217B1 (ko) 2017-12-27 2018-12-19 클루이베로마이세스 락티스 효모를 기본으로 하는 보호성 1가- 및 다가 서브유닛 백신의 생산을 위한 최적화된 숙주/벡터 시스템
HUE18857443A HUE068358T2 (hu) 2017-12-27 2018-12-19 Kluyveromyces lactis élesztõn alapuló, optimalizált gazda/vektor-rendszer protektív mono- és multivalens alegységvakcina elõállítására
DE112018006647.9T DE112018006647A5 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter
HRP20241297TT HRP20241297T1 (hr) 2017-12-27 2018-12-19 Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis
EP18857443.8A EP3732293B1 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis
US16/958,170 US11905517B2 (en) 2017-12-27 2018-12-19 Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
PL18857443.8T PL3732293T3 (pl) 2017-12-27 2018-12-19 Zoptymalizowany system gospodarz/wektor do wytwarzania ochronnych mono- i poliwalentnych szczepionek podjednostkowych na bazie drożdży kluyveromyces lactis
PT188574438T PT3732293T (pt) 2017-12-27 2018-12-19 Sistema otimizado hospedeiro/vetor para criação de vacinas protetoras de subunidade monovalentes e multivalentes à base da levedura kluyveromyces lactis
CN201880083894.1A CN111801422B (zh) 2017-12-27 2018-12-19 基于乳酸克鲁维酵母产生保护性单价和多价亚单位疫苗的优化的宿主/载体系统
BR112020013245-4A BR112020013245A2 (pt) 2017-12-27 2018-12-19 sistema hospedeiro/vetor otimizado para a produção de vacinas de subunidades mono- e multivalentes protetoras à base da levedura kluyveromyces lactis
ZA2020/03553A ZA202003553B (en) 2017-12-27 2020-06-12 Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast kluyveromyces lactis
JP2023132434A JP2023166412A (ja) 2017-12-27 2023-08-16 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム
US18/481,345 US12473562B2 (en) 2017-12-27 2023-10-05 Optimized host/vector system for producing protective mono-and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102017012109.5A DE102017012109A1 (de) 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis

Publications (1)

Publication Number Publication Date
DE102017012109A1 true DE102017012109A1 (de) 2019-06-27

Family

ID=65817691

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102017012109.5A Ceased DE102017012109A1 (de) 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
DE112018006647.9T Withdrawn DE112018006647A5 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE112018006647.9T Withdrawn DE112018006647A5 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter

Country Status (18)

Country Link
US (2) US11905517B2 (enExample)
EP (1) EP3732293B1 (enExample)
JP (2) JP7782951B2 (enExample)
KR (1) KR102704217B1 (enExample)
CN (1) CN111801422B (enExample)
BR (1) BR112020013245A2 (enExample)
CA (1) CA3086598A1 (enExample)
DE (2) DE102017012109A1 (enExample)
DK (1) DK3732293T3 (enExample)
EA (1) EA202091435A1 (enExample)
ES (1) ES2990197T3 (enExample)
HR (1) HRP20241297T1 (enExample)
HU (1) HUE068358T2 (enExample)
MX (1) MX2020006846A (enExample)
PL (1) PL3732293T3 (enExample)
PT (1) PT3732293T (enExample)
WO (1) WO2019129321A2 (enExample)
ZA (1) ZA202003553B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022101456A1 (en) * 2020-11-13 2022-05-19 Serymun Yeast Gmbh Yeast platform for the production of vaccines

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119391747B (zh) * 2024-12-12 2025-11-18 华中农业大学 一种利用马克斯克鲁维酵母制备禽传染性法氏囊病vp2纳米颗粒口服疫苗的方法及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
WO2006044923A2 (en) 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
US20070166323A1 (en) 2000-11-15 2007-07-19 Regents Of The University Of Colorado Yeast-dendritic cell vaccines and uses thereof
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
US7465454B2 (en) 2002-12-16 2008-12-16 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2010054649A2 (de) 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen/mukosalen vakzinierung mittels rekombinanter hefen
WO2013107436A1 (de) 2011-12-13 2013-07-25 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US20070166323A1 (en) 2000-11-15 2007-07-19 Regents Of The University Of Colorado Yeast-dendritic cell vaccines and uses thereof
US20090304741A1 (en) 2000-11-15 2009-12-10 Globelmmune, Inc. Yeast-Dendritic Cell Vaccines and Uses Thereof
US7465454B2 (en) 2002-12-16 2008-12-16 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2006044923A2 (en) 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
WO2010054649A2 (de) 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen/mukosalen vakzinierung mittels rekombinanter hefen
WO2013107436A1 (de) 2011-12-13 2013-07-25 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
1. Internet-Recherche am 10.10.2018: www.ncbi.nlm.nih.gov Accession Nummer: GCA 000002515 02.07.2004 *
3. Internet-Recherche am 15.10.2018: www.ncbi.nlm.nih.gov Accession Nummer: JQ682640 02.05.2012 *
4. CURTO, P.; u. a.: Establishing the YEAST K: LACTIS as an expression host for production of the Saposin-like domain of the aspartic protease Cirsin. 2014. In: Applied and Environmental Microbiology, S. 86-96 *
Remington's Practice of Pharmacy, 13. Ausgabe und J. of. Pharmaceutical Science & Technology, Vol. 52, Nr. 5, Sept-Okt., S. 238-311

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022101456A1 (en) * 2020-11-13 2022-05-19 Serymun Yeast Gmbh Yeast platform for the production of vaccines
EP4001417A1 (en) * 2020-11-13 2022-05-25 serYmun Yeast GmbH Yeast platform for the production of vaccines

Also Published As

Publication number Publication date
KR20200104367A (ko) 2020-09-03
KR102704217B1 (ko) 2024-09-09
WO2019129321A2 (de) 2019-07-04
CA3086598A1 (en) 2019-07-04
JP7782951B2 (ja) 2025-12-09
PT3732293T (pt) 2024-10-09
JP2021508496A (ja) 2021-03-11
MX2020006846A (es) 2020-11-06
DE112018006647A5 (de) 2020-10-01
HUE068358T2 (hu) 2024-12-28
ZA202003553B (en) 2021-06-30
ES2990197T3 (es) 2024-11-29
DK3732293T3 (da) 2024-09-23
CN111801422A (zh) 2020-10-20
WO2019129321A3 (de) 2019-09-12
EP3732293A2 (de) 2020-11-04
PL3732293T3 (pl) 2024-11-18
US20240102031A1 (en) 2024-03-28
US11905517B2 (en) 2024-02-20
BR112020013245A2 (pt) 2020-12-01
EA202091435A1 (ru) 2020-08-28
EP3732293B1 (de) 2024-07-03
CN111801422B (zh) 2024-06-14
JP2023166412A (ja) 2023-11-21
US20210230612A1 (en) 2021-07-29
HRP20241297T1 (hr) 2024-12-20
US12473562B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
DE60314823T3 (de) Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
KR100880765B1 (ko) 변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
DE60010358T2 (de) Infectiösenbursalkrankheitsvirus (IBDV) die an Zellkultur angepasst sind
US10704028B2 (en) Duck enteritis virus and the uses thereof
JP6990814B2 (ja) アヒル腸炎ウイルス及びその使用
CN110218706B (zh) 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用
US12473562B2 (en) Optimized host/vector system for producing protective mono-and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
EP2844759B1 (de) Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene
DE69332393T2 (de) Rekombinanter Katzen-Herpesvirus-Impfstoff
CN109562157A (zh) 多价重组spv
US10190099B2 (en) IBV strains and uses thereof
DE102013004595A1 (de) RSV-Impfstoffe
DE60028365T2 (de) Chimäre nukleinsäuren und polypeptide aus lyssavirus
DE102008057451A1 (de) Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
EA045050B1 (ru) Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis
CN119193692A (zh) 基于CRISPR/Cas9的制备方法及疫苗株和应用
DE10249594A1 (de) Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV)
KR20100044466A (ko) 환경에서 생존이 불가능한 박테리아를 함유하는 생백신 조성물

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R081 Change of applicant/patentee

Owner name: VEROVACCINES GMBH, DE

Free format text: FORMER OWNER: MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG, 06108 HALLE, DE

R082 Change of representative

Representative=s name: MAIKOWSKI & NINNEMANN PATENTANWAELTE PARTNERSC, DE

R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final